Key Points
- SVP Lori Winkler sold 2,650 shares on March 12 at an average price of $94.66 for about $250,849, trimming her stake by 20.58% to 10,224 shares.
- Zimmer Biomet beat Q4 estimates with $2.42 EPS and $2.24 billion revenue (up 10.9% y/y) and issued FY2026 guidance of $8.30–$8.45 EPS.
- The stock carries a consensus "Hold" rating with a $106.20 price target, pays a $0.24 quarterly dividend (1.0% yield), and faces mixed analyst opinions (1 Strong Buy, 8 Buy, 10 Hold, 3 Sell).
Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) SVP Lori Winkler sold 2,650 shares of the business's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the sale, the senior vice president owned 10,224 shares in the company, valued at $967,803.84. The trade was a 20.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Zimmer Biomet Stock Performance
Shares of Zimmer Biomet stock opened at $93.36 on Tuesday. The company has a 50 day moving average price of $92.42 and a 200 day moving average price of $95.03. The firm has a market capitalization of $18.27 billion, a P/E ratio of 26.37, a PEG ratio of 1.90 and a beta of 0.58. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. Zimmer Biomet Holdings, Inc. has a 52 week low of $84.59 and a 52 week high of $114.44.
Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. During the same quarter in the previous year, the firm earned $2.31 EPS. Zimmer Biomet's revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.
Zimmer Biomet Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet's dividend payout ratio is presently 27.12%.
Analyst Ratings Changes
A number of analysts have commented on the company. Wells Fargo & Company lifted their price target on Zimmer Biomet from $93.00 to $98.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 11th. BTIG Research restated a "buy" rating and issued a $112.00 price objective on shares of Zimmer Biomet in a research note on Tuesday, February 10th. UBS Group reaffirmed a "sell" rating and set a $89.00 target price on shares of Zimmer Biomet in a report on Wednesday, February 11th. Robert W. Baird reiterated a "neutral" rating and issued a $100.00 target price (down from $117.00) on shares of Zimmer Biomet in a research report on Tuesday, December 16th. Finally, Wall Street Zen lowered shares of Zimmer Biomet from a "buy" rating to a "hold" rating in a research report on Saturday, February 14th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of "Hold" and a consensus price target of $106.20.
Check Out Our Latest Stock Report on ZBH
Hedge Funds Weigh In On Zimmer Biomet
A number of institutional investors have recently modified their holdings of the stock. Rakuten Investment Management Inc. purchased a new position in shares of Zimmer Biomet during the 3rd quarter valued at approximately $37,307,000. Sector Gamma AS boosted its holdings in Zimmer Biomet by 28.0% during the third quarter. Sector Gamma AS now owns 113,478 shares of the medical equipment provider's stock worth $11,178,000 after buying an additional 24,847 shares in the last quarter. SG Americas Securities LLC grew its position in Zimmer Biomet by 29.2% during the third quarter. SG Americas Securities LLC now owns 61,110 shares of the medical equipment provider's stock valued at $6,019,000 after buying an additional 13,812 shares during the period. Border to Coast Pensions Partnership Ltd grew its position in Zimmer Biomet by 6.5% during the third quarter. Border to Coast Pensions Partnership Ltd now owns 360,462 shares of the medical equipment provider's stock valued at $35,506,000 after buying an additional 22,104 shares during the period. Finally, National Pension Service increased its holdings in Zimmer Biomet by 4.5% in the third quarter. National Pension Service now owns 393,476 shares of the medical equipment provider's stock valued at $38,757,000 after buying an additional 16,928 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company's stock.
Zimmer Biomet Company Profile
(
Get Free Report)
Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.
The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
